BMRN:NASDAQ
Biomarin Pharmaceutical Inc
54,80 $
arrow_downward
-0,17%(-0,095) 1D
54,80 $
0,00% (0,00)
bedtimeAfter hours
Closed: 9 հոկ, 16:00:01 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BMRN...
Open
54,80 $
High
55,98 $
Low
54,48 $
Mkt. cap
10,61 մլրդ
Avg. vol.
2,07 մլն
Volume
2,15 մլն
P/E ratio
147,72
52-wk high
70,98 $
52-wk low
49,26 $
EPS
0,37 $
Beta
0,22
Shares outstanding
193,57 մլն
No. of employees
3 հզր
Open
54,80 $
High
55,98 $
Low
54,48 $
Mkt. cap
10,61 մլրդ
Avg. vol.
2,07 մլն
Volume
2,15 մլն
P/E ratio
147,72
52-wk high
70,98 $
52-wk low
49,26 $
EPS
0,37 $
Beta
0,22
Shares outstanding
193,57 մլն
No. of employees
3 հզր
News stories
From web sources and news partners
The Globe and Mail
·
21 ժամ առաջ
Bank of America Securities Sticks to Its Buy Rating for BioMarin Pharmaceutical (BMRN)
TipRanks
·
1 օր առաջ
BioMarin Stock Slips As Pipeline Hype Fails To Impress
Simply Wall Street
·
2 օր առաջ
Is BioMarin Pharmaceutical (BMRN) Below Fair Value After New Clinical Data And Its AI Deal?
Profile
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria.
Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials. Wikipedia
About Biomarin Pharmaceutical Inc
CEOAlexander Hardy
Employees3,22 հզր
Foundedմրտ 1997
HeadquartersՍան Ռաֆայել, Կալիֆոռնիա, Միացյալ Նահանգներ
Sector-
Websitebiomarin.com